€0.03 close for Deinove SA (ALDEI.PA, EURONEXT) 29 Jan 2026: high volume insight
ALDEI.PA stock closed the EURONEXT session on 29 Jan 2026 at €0.0265, with 13,014,939 shares traded, making it one of the most active small-caps on Europe’s exchange today. Volume was 2.17x the average, pushing the price to a intraday high of €0.0321 and a low of €0.0231. Traders focused on liquidity and speculative flows, while fundamentals show a biotech firm still funding R&D with negative EPS of -0.24. We review trading drivers, financials, sector context and Meyka AI’s grade and forecast for ALDEI.PA stock.
Market activity and trading snapshot for ALDEI.PA stock
Deinove SA (ALDEI.PA) finished the market closed session at €0.0265 with daily range €0.0231–€0.0321. Volume 13,014,939 vs average 5,992,347 produced a relative volume of 2.17, indicating higher-than-normal trader interest. Daily open was €0.0239 and previous close matched €0.0265.
Financial snapshot and valuation metrics for ALDEI.PA stock
The company reports EPS -0.24 and a negative P/E; market cap sits at €1,134,989.00 and enterprise value at €3,613,989.00. Price to sales ratio is 3.09 and book value per share is negative at -€0.46. Current ratio is 1.36, and cash per share is €0.13, showing limited liquidity cushion for the biotech development cycle.
Technicals and short-term trading signals for ALDEI.PA stock
Short-term momentum shows the 50-day average at €0.02315 vs 200-day at €0.11427, flagging a long-term downtrend with a short-term uptick. The stock’s year high €0.4360 and year low €0.0062 reflect extreme volatility over 12 months. Traders watching active liquidity will note the high intraday range and elevated relative volume as triggers for short-term setups.
Sector context: Healthcare and biotech comparison for ALDEI.PA stock
Deinove is in Healthcare, Biotechnology; the sector YTD performance is muted versus broader markets, with Healthcare 1Y around +4.32% and YTD +0.53%. As a small-cap biotech, ALDEI.PA stock faces higher beta and funding risk compared with larger peers like Sanofi. Partnerships with bioM rieux and Institut Pasteur are positives for development validation.
Meyka AI rates ALDEI.PA with a score out of 100 and valuation view
Meyka AI rates ALDEI.PA with a score out of 100: 61.03 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 comparison, sector and industry metrics, financial growth, key ratios, analyst consensus and forecasts. Enterprise metrics and cash position weigh on the rating, while product-stage assets and partnerships provide upside potential.
Risks, catalysts and near-term outlook for ALDEI.PA stock
Key risks include continued cash burn, negative operating margins and dependency on R&D milestones. Catalysts that could drive price are clinical trial updates for DNV3837, new commercial deals for cosmetic ingredients, or capital raises. Liquidity is both an opportunity and a risk: high trading volume can amplify moves, but market depth remains limited at microcap market cap levels.
Final Thoughts
ALDEI.PA stock closed the EURONEXT session on 29 Jan 2026 at €0.0265, with unusually high volume (13,014,939) and a relative volume of 2.17 that marked it among the most active names today. Fundamentals show negative EPS (-0.24) and a small market cap (€1,134,989.00), consistent with a development-stage biotech reliant on partnerships and periodic capital events. Meyka AI’s forecast model projects a 12-month base target of €0.0450, implying an upside of 69.81% from the current €0.0265 price; forecasts are model-based projections and not guarantees. Given the mix of elevated trading activity, thin capitalization, and milestone-driven upside, our view frames ALDEI.PA stock as higher risk, higher volatility—appropriate for speculative allocations or as a monitored watchlist position. Traders should weigh liquidity-driven price moves against long-term financing and trial-readout timelines before initiating larger positions. For more company details visit the official site and public filings source and reference financial data at FinancialModelingPrep source. Meyka AI — our AI-powered market analysis platform — provides these models and grades for research purposes, not investment advice.
FAQs
What drove ALDEI.PA stock activity today?
High liquidity drove activity: 13,014,939 shares traded, about 2.17x average. Volume growth often reflects speculative flows, news scanning, or technical trading in microcap biotech names.
What is Meyka AI’s grade and what does it mean for ALDEI.PA stock?
Meyka AI rates ALDEI.PA 61.03/100 (B, HOLD). The grade balances sector and benchmark comparisons with financial metrics and forecasts to indicate cautious monitoring rather than a clear buy signal.
What price target does Meyka AI forecast for ALDEI.PA stock?
Meyka AI’s forecast model projects a 12-month base target of €0.0450, implying +69.81% from current €0.0265. Forecasts are model-based projections and not guarantees.
How risky is investing in ALDEI.PA stock?
ALDEI.PA stock is high risk due to negative earnings, small market cap (€1.13M), and milestone-driven valuation. It is suitable for speculative portfolios or as a monitored position rather than core holdings.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
